Esophageal cancer is the sixth most common cancer worldwide but has a unique geographic and ethnic distribution[@b1], with a higher incidence in Asia than in the West. In some endemic districts in northern and central China, its incidence exceeds 100 cases per 100 000 people per year, comprising 78% of annual new cases and 76% of annual deaths of total carcinoma cases[@b2]. Esophageal cancer has two main types with different etiologic and pathologic characteristics: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma[@b3]. Notably, ESCC is the predominant type and accounts for approximately 90% of esophageal cancer cases worldwide[@b4]. Although the overall effectiveness of surgical and medical treatments for ESCC has improved in recent years, its prognosis still remains poor, with a 5-year survival rate of less than 10% for the patients[@b5]. Thus, elucidating the molecular mechanisms of ESCC pathogenesis will help to identify specific tumor markers for early detection, risk assessment, and therapeutic targeting.

Both genetic and epigenetic alterations contribute to the initiation and progression of ESCC. Genetic abnormalities involved in ESCC tumorigenesis include chromosomal loss and gain, loss of heterozygosity (LOH), and gene amplification and mutation[@b6]. Recently, epigenetic disruptions, including promoter CpG island methylation of tumor suppressor genes (TSGs) and microRNA methylation[@b7],[@b8], have been recognized as key events in ESCC development. Here, we provide an overview of aberrant promoter methylation of critical TSGs in ESCC and the potential of these alterations as both tumor markers and therapeutic targets for ESCC.

TSGs Silenced by Promoter Methylation in ESCC {#s2}
=============================================

We briefly summarized the epigenetically silenced TSGs in ESCC according to their biological functions, such as apoptosis, cell cycle control, cell adhesion, and DNA repair ([Table 1](#cjc-32-01-003-t01){ref-type="table"}). Major functional groups are briefly reviewed below.

###### Summary of tumor suppressor genes (TSGs) silenced by promoter methylation in esophageal squamous cell carcinoma (ESCC)

  Classification                                                                Gene name                                                          Full name                                                     Location                                          Major functions                 Reference(s)
  ---------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------ ----------------
  Cell cycle control genes                                                        *CHFR*                                       Checkpoint with forkhead and ring finger domains                                  12q24.33                                         Cell cycle control                  [@b16]
  *p14^ARF^/CDKN2A*                                                Cyclin-dependent kinase inhibitor 2A                                              9p21                                           Stabilizing p53, cell cycle control                             [@b11],[@b19]                
  *p15^INK4b^/CDKN2B*                                              Cyclin-dependent kinase inhibitor 2B                                              9p21                                                   Cell cycle control                                          [@b11]                   
  *p16^INK4a^/CDKN2A*                                              Cyclin-dependent kinase inhibitor 2A                                              9p21                                                   Cell cycle control                                      [@b11],[@b19]                
  *RASSF1A*                                                          RAS association domain family 1A                                               3p21.3                                             Cell cycle control, apoptosis                                    [@b14]                   
  Pro-apoptotic genes                                                             *DAPK*                                                Death-associated protein kinase                                           9q34.1                                              Apoptosis                   [@b19],[@b67]
  *RUNX3*                                                          Runt-related transcription factor 3                                               1p36                                                  Transcription factor                                  [@b14],[@b21],[@b22]            
  *UCHL1*                                                        Ubiquitin carboxyl-terminal hydrolase L1                                            4p14                                            Cell growth inhibition, apoptosis                              [@b23],[@b24]                
  *ZNF382*                                                               Zinc finger protein 382                                                   19q13.12                                         Pro-apoptotic transcription factor                                  [@b77]                   
  Metastasis-antagonizing genes                                                   *CDH1*                                                    Cadherin 1, E-cadherin                                                16q22.1                              Cell adhesion, proliferation, metastasis   [@b27]--[@b29]
  *CDH11*                                                                Cadherin 11, OB-cadherin                                                    16q21                                       Cell adhesion, proliferation, metastasis                               [@b30]                   
  *CDH13*                                                                Cadherin 13, H-cadherin                                                    16q23.3                                      Cell adhesion, proliferation, metastasis                               [@b31]                   
  *CLDN3*                                                                       Claudin 3                                                           7q11.23                                                 Cell-cell adhesion                                          [@b32]                   
  *CLDN4*                                                                       Claudin 4                                                           7q11.23                                                  Adhesion melocule                                          [@b33]                   
  *DCC*                                                              Deleted in colorectal carcinoma                                                18q21.3                                      Cell adhesion, differentiation, apoptosis                              [@b34]                   
  *LRP1B*                                                  Low density lipoprotein receptor-related protein 1B                                      2q21.2                                                       Migration                                              [@b35]                   
  *PCDH10*                                                                   Protocadherin 10                                                       4q28.3                                                 Cell-cell connection                                         [@b36]                   
  *PCDH17*                                                                   Protocadherin 17                                                       13q21.1                                                Cell-cell connection                                         [@b37]                   
  *TSLC1*                                                           Tumor suppressor in lung cancer 1                                               11q23.2                                                    Cell adhesion                                            [@b38]                   
  *UPK1A*                                                                      Uroplakin-1A                                                        19q13.13                                          Tetraspanin cell surface receptor                                  [@b72]                   
  DNA repair genes                                                                *FHIT*                                                    Fragile histidine triad                                               3p14.2                               Cell cycle control, DNA-damage response    [@b53]--[@b55]
  *MGMT*                                                          O6-methylguanine-DNA methyltransferase                                             10q26                                                      DNA repair                                          [@b41]--[@b44]               
  *MLH1*                                                                   Human mutL homolog 1                                                     3p21.3                                            DNA repair, cell cycle control                                [@b47]--[@b49]               
  *MSH2*                                                                   Human mutS homolog 2                                                      2p21                                         DNA mismatch repair, cell cycle control                               [@b50]                   
  Growth factor response-related genes                                           *CRBP1*                                              Retinol-binding protein 1, cellular                                          3q23                                           Retinol transport                   [@b78]
  *CRABP1*                                                       Cellular retinoic acid-binding protein 1                                            15q24                                           Differentiation and proliferation                                  [@b79]                   
  *DAB2*                                                  Disabled homolog 2, mitogen-responsive phosphoprotein                                      5p13                                       Growth factor response, blocks Ras activity                             [@b80]                   
  *RARB*                                                               Retinoic acid receptor, beta                                                  3p24                                             Cell growth and differentiation                            [@b3],[@b58]--[@b61]            
  *RARRES1*                                              Retinoic acid receptor responder (tazarotene induced) 1                                    3q25.32                                                 Retinoid signaling                                          [@b81]                   
  *SOCS1*                                                           Suppressor of cytokine signaling 1                                             16p13.13                                       Negative regulator of JAK/STAT pathway                                [@b78]                   
  WNT signaling-related genes                                                     *APC*                                                   Adenomatous polyposis coli                                             5q21--q22                             Cell polarity and chromosome segregation       [@b69]
  *SFRP1*                                                          Secreted frizzled-related protein 1                                              8p11.21                                         Antagonist of WNT protein receptors                             [@b19],[@b82]                
  *SFRP2*                                                          Secreted frizzled-related protein 2                                              4q31.3                                          Antagonist of WNT protein receptors                                 [@b19]                   
  *SOX17*                                                                       SRY box 17                                                          8q11.23                                                   WNT antagonist                                            [@b83]                   
  *WIF1*                                                                 Wnt inhibitory factor 1                                                    12q14.3                                           WNT-signaling pathway inhibitor                                   [@b84]                   
  *WNT5A*                                                 Wingless-type MMTV integration site family, member 5A                                    3p21--p14                                          WNT-signaling pathway inhibitor                                   [@b85]                   
  Other genes with tumor suppressive functions                                  *ADAMTS9*                                  ADAM metallopeptidase with thrombospondin type 1 motif, 9                              3p14.1                                      Metallopeptidase activity               [@b86]
  *ADAMTS18*                                            ADAM metallopeptidase with thrombospondin type 1 motif, 18                                   16q23                                               Metallopeptidase activity                                      [@b87]                   
  *BLU/ZMYND10*                                                    Zinc finger, MYND-type containing 10                                             3p21.3                                         Stress-response, transcription factor                                [@b88]                   
  *CACNA1G*                                            Calcium channel, voltage-dependent, T type, alpha 1G subunit                                  17q22                                           Cell proliferation and cell death                                  [@b19]                   
  *CDX2*                                                                  Caudal type homeobox 2                                                    13q12.3                                            Transcription factor activity                                    [@b89]                   
  *CMTM3*                                                   CKLF-like MARVEL transmembrane domain containing 3                                       16q21                                                  Chemokine activity                                          [@b90]                   
  *CMTM5*                                                   CKLF-like MARVEL transmembrane domain containing 5                                      14q11.2                                                 Chemokine activity                                          [@b91]                   
  *DLC1*                                                                Deleted in liver cancer 1                                                    8p22                              Cytoskeleton organization, signal transduction, cell adhesion                    [@b92]                   
  *DLEC1*                                                        Deleted in lung and esophageal cancer 1                                          3p22--p21.3                                               Signal transduction                                         [@b93]                   
  *ECRG4*                                                        Esophageal cancer-related gene 4 protein                                           2q12.2                                                        Unknown                                               [@b94]                   
  *EDNRB*                                                               Endothelin receptor type B                                                   13q22                                          G-protein-coupled receptor activity                                 [@b95]                   
  *EMP3*                                                              Epithelial membrane protein 3                                                 19q13.3                                                       Unknown                                               [@b96]                   
  *ENG*                                                                          Endoglin                                                         9q33--q34.1                                               Signal transduction                                         [@b97]                   
  *GATA4*                                                                 GATA-binding protein 4                                                  8p23.1--p22                                        Zinc-finger transcription factor                                   [@b98]                   
  *GATA5*                                                                 GATA-binding protein 5                                                   20q13.33                                          Zinc-finger transcription factor                                   [@b98]                   
  *GPX3*                                                                 Glutathione peroxidase 3                                                    5q23                                      Catalyzes the reduction of hydrogen peroxide                             [@b99]                   
  *GSTP1*                                                             Glutathione S-transferase pi 1                                                 11q13                                           Glutathione transferase activity                                  [@b100]                   
  *HIN1/SCGB3A1*                                                    Secretoglobin, family 3A, member 1                                            5q35--qter                                                Signal transduction                                        [@b101]                   
  *HLA-I*                                                                      HLA class I                                                          6p21.3                                                    Immune response                                          [@b102]                   
  *HLTF*                                                            Helicase-like transcription factor                                           3q25.1--q26.1                                        Helicase and ATPase activities                                   [@b103]                   
  *HOPX*                                                                       HOP homeobox                                                          4q12                                              Regulation of gene expression                                   [@b104]                   
  *HSPB2*                                                               Heat shock 27kDa protein 2                                                11q22--q23                                            Heat shock protein activity                                    [@b105]                   
  *ITGA4*                                                                   Integrin, alpha 4                                                       2q31.3                                        Cell communication, signal transduction                               [@b29]                   
  *IRF8*                                                              Interferon regulatory factor 8                                                16q24.1                                            Transcription factor activity                                   [@b106]                   
  *MT1G*                                                                    Metallothionein 1G                                                       16q13                                               Cellular stress response                                       [@b32]                   
  *MT3*                                                                     Metallothionein 3                                                        16q13                                                   Growth inhibition                                         [@b107]                   
  *NMDAR2B*                                              Glutamate receptor, ionotropic, N-methyl D-aspartate 2B                                     12p12                                                  Signal transduction                                         [@b70]                   
  *NEFH*                                                             Neurofilament, heavy polypeptide                                               22q12.2                                           Cell growth and/or maintenance                                   [@b108]                   
  *NELL1*                                                                       NEL-like 1                                                          11p15.1                                     Cell growth regulation and differentiation                             [@b109]                   
  *P300/EP300*                                                          E1 A-binding protein p300                                                   22q13.2                                          Transcription regulator activity                                  [@b110]                   
  *PCAF/KAT2B*                                                        K(lysine) acetyltransferase 2B                                                 3p24                                            Transcription regulator activity                                  [@b111]                   
  *PLCD1*                                                                Phospholipase C, delta 1                                                 3p22--p21.3                                             Phospholipase activity                                       [@b112]                   
  *SST*                                                                        Somatostatin                                                          3q28                                                  Somatostatin hormone                                        [@b113]                   
  *TAC1*                                                                 Tachykinin, precursor 1                                                   7q21--q22                                            Tachykinin peptide hormone                                      [@b65]                   
  *THSD1*                                                      Thrombospondin, type I, domain containing 1                                          13q14.3                                                       Unknown                                           [@b71],[@b114]               
  *TIMP3*                                                           TIMP metallopeptidase inhibitor 3                                               22q12.3                                             Metalloproteinase inhibitor                                     [@b71]                   
  *TPEF/TMEFF2*                                   Transmembrane protein with EGF-like and two follistatin-like domains 2                            2q32.3                                                 Transmembrane protein                                       [@b115]                   
  *Trypsinogen 4*                                                             Trypsinogen 4                                                         9p11.2                                                 Proteolytic activity                                        [@b116]                   
  *VHL*                                                             von Hippel-Lindau tumor suppressor                                               3p25                                               Ubiquitin ligase component                                     [@b117]                   

ADAM, disintegrin and metalloprotease domain; CKLF, chemokine-like factor; HLA, human leukocyte antigen; HOP, homeodomain-only protein; MYND, myeloid, Nervy, and DEAF-1; NEL, neural epidermal growth factor-like; SRY, sex-determining region Y; TIMP, tissue inhibitor of metalloproteinase 1.

Cell cycle control genes {#s2a}
------------------------

*p16^INK4a^* and *p14^ARF^*, transcripts of the cyclin-dependent kinase inhibitor 2A (*CDKN2A*) locus on chromosome 9p21, are two well-studied TSGs that are inactivated by genetic or epigenetic alterations in multiple malignancies[@b9],[@b10]. In ESCC, *p16^INK4a^* was methylated in 40%--61% of primary tumors and was less frequently inactivated due to homozygous deletion or mutation[@b11],[@b12], whereas *p14^ARF^* was methylated at a low frequency (13%--15%) and was mainly inactivated due to homozygous deletion[@b11]. These results suggest that promoter methylation is the predominant mechanism for *p16^INK4a^* inactivation but not *p14^ARF^* during ESCC pathogenesis [@b11].

As a gatekeeper for G~1~/S cell cycle progression, the RAS association domain family 1A (*RASSF1A*) gene is epigenetically inactivated in a broad spectrum of tumors[@b13]. In ESCC, *RASSF1A* was methylated in 51% of primary tumors, but rarely in matched non-cancerous tissues[@b14]. In addition, *RASSF1A* methylation was correlated with the clinical stage of ESCC[@b14]. Remarkably, the frequency of *RASSF1A* methylation in Chinese ESCC patients was relatively lower than that in Japanese ESCC patients[@b15], indicating that a possibly different mechanism is involved in *RASSF1A* methylation among these populations. Other cell cycle control genes silenced by promoter methylation have also been reported in ESCC, such as *p15^INK4b^* and checkpoint with forkhead and ring finger domains (*CHFR*)[@b11],[@b16] ([Table 1](#cjc-32-01-003-t01){ref-type="table"}).

Pro-apoptotic genes {#s2b}
-------------------

Death-associated protein kinase (*DAPK*), a gene that encodes a pro-apoptotic serine/threonine kinase, participates in various apoptotic pathways in response to tumor necrosis factor-α (TNF-α), Fas ligand, Ceramide, tumor growth factor-β (TGF-β), arsenic trioxide, and detachment from the extracellular matrix[@b17],[@b18]. Promoter methylation of *DAPK* was frequently detected in intraepithelial lesions and primary ESCC[@b19], but rarely in normal and non-neoplastic epithelia, suggesting a role of methylation-mediated *DAPK* silencing in ESCC progression.

The runt-related transcription factor 3 (*RUNX3*) gene encodes RUNX3, a pro-apoptotic factor in the TGF-β signaling pathway that is commonly silenced in a variety of human tumors[@b20]. In ESCC, *RUNX3* silencing by promoter methylation[@b21] induced tumor progression and worsened patient prognosis[@b22]. As different frequencies of *RUNX3* methylation were reported in ESCC, the precise CpG region at which the *RUNX3* promoter is methylated for silencing needs to be further confirmed.

In addition, other novel methylated pro-apoptotic genes have been identified in ESCC. For instance, Ubiquitin carboxyl-terminal hydrolase L1 (*UCHL1*), located on chromosome 4p14, can induce apoptosis through the intrinsic, caspase-dependent pathway[@b23]. Studies showed that *UCHL1* was methylated in 40% of primary ESCCs but not in the paired adjacent non-tumor tissues[@b23]. Furthermore, *UCHL1* methylation was correlated with regional lymph node metastasis[@b24]. These findings indicate that *UCHL1* may serve as an independent prognostic factor for ESCC patient survival.

Metastasis-antagonizing genes {#s2c}
-----------------------------

Cadherin 1 (*CDH1*), which encodes a transmembrane glycoprotein, is a classic TSG at 16q22.1 and acts as a key cell-cell adhesion molecule to maintain normal tissue architecture and inhibit tumor initiation[@b25]. The inactivation of *CDH1* occurs at different stages of tumorigenesis, even at an early stage[@b26]. *CDH1* silencing with promoter methylation was detected in 41%--80% of primary ESCCs, which is related with poor survival of patients with stage I and stage II ESCC[@b27]--[@b29]. Similarly, other genes related to cell adhesion silenced by promoter methylation, such as cadherin 11 (*CDH11*)[@b30], cadherin 13 (*CDH13*)[@b31] claudin 3 (*CLDN3*)[@b32], claudin 4 (*CLDN4*)[@b33], deleted in colorectal carcinoma (*DCC*)[@b34], low density lipoprotein receptor-related protein 1B (*LRP1B*)[@b35], protocadherin 10 (*PCDH10*)[@b36], protocadherin 17 (*PCDH17*)[@b37], and tumor suppressor in lung cancer 1 (*TSLC1*)[@b38], have already been determined to be involved in tumor invasion and metastasis of ESCC ([Table 1](#cjc-32-01-003-t01){ref-type="table"}).

DNA repair genes {#s2d}
----------------

The product of the O-6-methylguanine-DNA methyl-transferase (*MGMT*) gene mediates a unique DNA repair pathway by removing methyl/alkyl groups from O-6-alkyl-guanine (G) and thus protects cells from mutagenic and cytotoxic effects of alkylating agents[@b39]. *MGMT* was reported to be epigenetically silenced in about 30% of human cancers due to promoter methylation[@b40]. In ESCC, *MGMT* methylation was increased along with tumor progression[@b41]. Notably, *MGMT* methylation was associated with *TP53* mutations[@b42] or the C677T polymorphism of 5, 10-methylenetetrahydrofolate (*MTHFR*) in ESCC patients[@b43],[@b44], suggesting a synergistic effect of both epigenetic and genetic mechanisms in ESCC pathogenesis.

Mismatch repair gene mutL homolog 1 (*MLH1*) was reported to be inactivated by genetic or epigenetic alterations in multiple human cancers[@b45],[@b46]. Promoter methylation of *MLH1*, which reduced its protein expression level, was detected in 62% of ESCCs[@b47]. Interestingly, epigenetically silenced *MLH1* was always associated with microsatellite instability in ESCC [@b48],[@b49], indicating that *MLH1* plays a critical role in ESCC progression. *MSH2*, another important DNA mismatch repair gene, was also silenced by promoter methylation in 32% of ESCCs but none of the matched normal tissues[@b50].

The fragile histidine triad (*FHIT*) gene, located at 3p14.2[@b51], plays an essential role in chromosomal abnormality and DNA damage[@b52]. *FHIT* was methylated in 69% of ESCCs but not in the matched normal tissues, and this methylation was responsible for decreased FHIT protein level[@b53]. Loss of FHIT expression was usually observed at initial stages of ESCC[@b54] and thus might serve as an independent prognostic marker and as a marker for early detection of ESCC[@b55]. In addition, aberrant methylation of *FHIT* can also be induced by nicotine[@b56], indicating its role in smoking-related ESCC tumorigenesis.

Growth factor response-related genes {#s2e}
------------------------------------

Retinoids play an important role in growth arrest and apoptosis via binding to specific nuclear retinoid receptors, such as retinoic acid receptor β (RARβ)[@b57]. Loss of expression of *RARB*, the gene encoding RARβ, was observed in 54% of ESCCs and 57% of dysplastic lesions [@b58], with no LOH detected[@b59]. Frequent promoter methylation of *RARB* was detected in primary ESCC tumors (70%), dysplastic lesions (58%), and basal cell hyperplasia (43%) but rarely in normal tissues, and methylation was related with ESCC grade[@b60]. Moreover, *RARB* expression could be reactivated by pharmacologic demethylation treatment[@b61]. These data suggest that *RARB* silencing by promoter methylation is an early event in ESCC development.

Promoter Methylation of TSGs as Tumor Markers for ESCC {#s3}
======================================================

Detecting promoter methylation of TSGs has advantages compared to protein or RNA analysis. First, DNA can be released outside of the tumor mass and is more stable than RNA or protein, which makes DNA-based markers easier to obtain from distinct types of biological fluid (such as sputum, pancreatic juice, and urine), blood and tissues (including 10% formaldehyde-fixed samples)[@b62]. Second, PCR-based analyses of DNA methylation have relatively high sensitivity. For example, methylation-specific PCR is able to detect a single methylated allele among 1000 unmethylated alleles, even in the presence of an abundance of normal DNA[@b63]. Third, because DNA used for methylation analysis is chemically stabilized, sample handling requirements are not rigid[@b64]. Thus, DNA methylation assays can be exploited as potent noninvasive diagnostic methods for clinical applications.

Given the high mortality, early detection or diagnosis is essential for successful treatment of ESCC. Promoter methylation of multiple TSGs, including *p16^INK4a^*, *p14^ARF^*, *FHIT, RARB, MGMT*, and tachykinin1 (*TAC1*), was detected in precancerous basal cell hyperplasia or dysplastic lesions, indicating their early diagnostic values in ESCC[@b19],[@b41],[@b61],[@b65]. Furthermore, a panel of four methylated genes, aryl-hydrocarbon receptor repressor (*AHRR*), *p16^INK4a^*, metallothionein 1G (*MT1G*), and *CLDN3*, was used to successfully screen esophageal balloon cytology samples with much better specificity and sensitivity compared with single-gene methylation[@b66]. Another panel of methylated genes, *RARB, DAPK, CDH1, p16^INK4a^*, and *RASSF1A*, had a diagnostic sensitivity of 82.2% and a specificity of 100% for ESCC in detecting serum DNA of ESCC patients[@b67]. These findings suggest that a cluster of methylated TSGs is more efficient for early detection of ESCC than single-gene methylation.

Since TNM staging has a limited capacity in assessing tumor prognosis, many studies have been performed to establish a reliable technique with which to predict prognosis in human cancers. Recently, the feasibility of TSG methylation as a predictor of clinical outcome after radical surgery has been studied in ESCC. For example, promoter methylation of *CDH1*[@b29], *FHIT*[@b55], and integrin alpha 4 (*ITGA4*)[@b29] can be used to stratify patients with stage I and II ESCC. Promoter methylation of *CDH1*[@b68] and *ITGA4*[@b29] have been linked to tumor recurrence, and methylation of other genes including adenomatous poly-posis coli (*APC*)[@b69], N-methyl D-aspartate 2B (*NMDAR2B*)[@b70], tachykinin 1 (*TAC1*)[@b65] TIMP metallopeptidase inhibitor 3 (*TIMP3*)[@b71], *UCHL1*[@b24], and uroplakin 1A (*UPK1A*)[@b72] have been linked to shorter survival.

Translational Applications of DNA Demethylation in ESCC Treatment {#s4}
=================================================================

Epigenetic reagents intended to reactivate epigenetically silenced TSGs or tumor antigens are being tested for their anticancer effects. Nucleoside analogues 5-azacytidine (azacytidine) or 5-aza-2′-deoxycytidine (decitabine) can effectively reverse silencing of multiple TSGs by blocking the activity of DNA methyltransferase (DNMT) in tumor cells, thereby exhibiting significant tumor suppressive activity[@b73]. These drugs have been approved by the US Food and Drug Administration (FDA) for treating myelodysplastic syndrome, a pre-leukemia disease. Recently, several novel DNMT inhibitors have also been reported for future clinical use, such as 5-fluoro-2′-deoxycytidine (Zebularine), epigallocatechin-3-gallate (EGCG), and RG108[@b64]. However, due to lack of specificity for target genes, more studies of demethylation therapy are currently being performed to prove the efficacy of this approach on solid tumors[@b74]. Although clinical trials using demethylation reagents have not been reported in ESCC yet, combining DNA demethylation agents with traditional chemotherapy drugs should be a promising prospect for ESCC treatment in future.

Conclusions {#s5}
===========

ESCC pathogenesis is a multistep process controlled by both genetic and epigenetic mechanisms. Silencing TSGs by promoter methylation plays essential roles in ESCC initiation and development. Numerous methylated genes have been identified in ESCC in recent years and thus provide new insights into the molecular mechanism of ESCC pathogenesis and expand the knowledge of tumor markers for clinical application. However, some issues remain to be solved in the future. For example, few methylated genes have been identified in ESCC by a single group, with the methylation frequency of some TSGs varying widely in different labs, probably due to different patient cohorts or detection methods[@b75]. With the use of genome-wide epigenomic approaches[@b76], the more reliable identification of methylated genes or gene panels might improve the early detection and prognosis of ESCC in future.
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